Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

COPENHAGEN (Reuters) -Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Novo Nordisk, maker of the popular weight-loss drug Wegovy, says it has started to increase the availability of the drug for people in the United States. CNN values your feedback 1.

Novo said the results from the late-stage drug trial showed patients taking the weekly injection of semaglutide, the active ingredient in Wegovy, had a 20% lower risk of heart attack, stroke or ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.